53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

Key Takeaways Explain This Topic AI

Diabetic nephropathy surveillance requires an annual spot Urine Albumin-to-Creatinine Ratio (UACR) and serum creatinine/eGFR; microalbuminuria is defined as 30-299 mg/g and macroalbuminuria as >=300 mg/g, requiring 2 of 3 abnormal specimens over 3 to 6 months to confirm; ACE inhibitors or ARBs are mandatory for hypertension with albuminuria >=30 mg/g, with SGLT2 inhibitors and finerenone added for progressive disease.

Diabetic retinopathy screening requires a dilated eye examination by an optometrist or ophthalmologist at diagnosis for T2D, and within 5 years of diagnosis for T1D; non-proliferative diabetic retinopathy (NPDR) is characterized by microaneurysms, dot-blot hemorrhages, and hard exudates, whereas proliferative diabetic retinopathy (PDR) features neovascularization and vitreous hemorrhage, treated with panretinal photocoagulation (PRP) or intravitreal anti-VEGF injections.

Diabetic macular edema (DME) is the leading cause of legal blindness in diabetes, can occur at any stage of retinopathy, and is treated primarily with intravitreal anti-VEGF agents (aflibercept, ranibizumab).

Annual diabetic foot examination requires 10-g Semmes-Weinstein monofilament testing to evaluate for loss of protective sensation (LOPS), visual inspection for deformities/ulcers, and vascular palpation/ABI; first-line pharmacotherapy for painful diabetic neuropathy includes duloxetine and pregabalin; acute unilateral warm, swollen foot without ulcer represents Charcot neuroarthropathy requiring immediate total contact casting.

Macrovascular risk reduction mandates blood pressure <130/80 mmHg, moderate-to-high intensity statin therapy, low-dose aspirin 81 mg daily for secondary prevention, and complete vaccination including annual influenza, PCV20 pneumococcal conjugate, hepatitis B series, RSV, COVID-19, and Tdap.

Last updated: September 2026

Diabetic Health Maintenance Protocol Overview

Chronic hyperglycemia exerts devastating pathophysiological damage across both the microvasculature (retinal capillaries, renal glomeruli, endoneurial microvessels) and macrovasculature (coronary arteries, cerebral circulation, peripheral arterial beds). Family physicians serve as the primary coordinators of systematic, longitudinal surveillance designed to identify early subclinical organ injury and deploy guideline-directed disease-modifying therapies. ANNUAL COMPREHENSIVE DIABETIC HEALTH MAINTENANCE SCHEDULE

Surveillance Domain Screening Modality & Frequency Diagnostic Target / Thresholds

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Glycemic Control HbA1c every 3 months (if uncontrolled) • Individualized target (<7.0% general;
or every 6 months (if stable at target) <6.5% young; <8.0-8.5% frail/elderly)

Diabetic Nephropathy Annual Spot Urine Albumin-to-Creatinine • Normal: UACR < 30 mg/g
Ratio (UACR) + Serum Creatinine / eGFR • Microalbuminuria: UACR 30 to 299 mg/g
Macroalbuminuria: UACR >= 300 mg/g

Diabetic Retinopathy Dilated eye exam by ophthalmologist/ • T2D: Start at diagnosis; annually
optometrist (every 1-2 years if normal) • T1D: Start within 5 yr of diagnosis

Diabetic Neuropathy & Annual Comprehensive Diabetic Foot Exam: • Loss of Protective Sensation (LOPS):

Foot Complications • 10-g Semmes-Weinstein monofilament failure to feel >= 1 of 10 sites
128-Hz vibration, pinprick, Achilles reflex • ABI < 0.90 confirms PAD
Visual skin/deformity exam, pedal pulses • Charcot detection (erythema/warmth)

Blood Pressure Surveillance Screened at every clinical visit • Target: < 130/80 mmHg for all adults

Lipid Panel Annual fasting or non-fasting lipid profile • Statin: Moderate-to-high intensity
Target LDL-C: < 70 or < 55 mg/dL

Dental & Periodontal Exam Annual professional dental evaluation • Periodontitis exacerbates dysglycemia

Microvascular Complication 1: Diabetic Nephropathy Surveillance & Intervention

Diabetic Kidney Disease (DKD) develops in 30% to 40% of patients with diabetes and represents the single leading cause of end-stage renal disease (ESRD) requiring chronic maintenance hemodialysis or renal transplantation in the United States.

Pathophysiological Natural History

Glomerular Hyperfiltration & Hypertrophy : Early hyperglycemia induces renal vasodilatation, predominantly driven by efferent arteriolar constriction (angiotensin II-mediated) and afferent arteriolar relaxation (SGLT2-mediated glucose/sodium hyper-reabsorption blunting tubuloglomerular feedback). This generates intense intraglomerular capillary hypertension.

Mesangial Expansion & Matrix Accumulation : Hyperglycemia induces advanced glycation end-products (AGEs) and transforming growth factor-beta (TGF-beta), stimulating mesangial cell proliferation and dense extracellular matrix deposition.

Basement Membrane Thickening & Podocyte Loss : Podocyte detachment and glomerular basement membrane thickening disrupt the filtration slit diaphragm, permitting albumin leakage.

Nodular Glomerulosclerosis (Kimmelstiel-Wilson Lesions) : Pathognomonic acellular, PAS-positive, eosinophilic nodular lesions form within glomerular mesangial areas, leading to progressive capillary obliteration, nephrotic-range proteinuria, and declining GFR.

Screening Protocol & Staging

Screening requires an annual random spot Urine Albumin-to-Creatinine Ratio (UACR) obtained from an early-morning first-void urine specimen, coupled with serum creatinine and estimated GFR (eGFR) : ALBUMINURIA STAGING & THE CONFIRMATION RULE

Stage Category UACR (mg/g) UACR (mg/mmol) Clinical Classification & Confirmation Rule
═════════════════════════════════════════════════════════════════════════════════════════════════════════

Stage A1 (Normal) < 30 mg/g < 3 mg/mmol Normal to mildly increased albumin excretion.

Stage A2 (Micro) 30 to 299 mg/g 3 to 30 mg/mmol Moderately increased albuminuria (Microalbuminuria).

Earliest clinical indicator of nephropathy.

Stage A3 (Macro) >= 300 mg/g > 30 mg/mmol Severely increased albuminuria (Macroalbuminuria).

High risk of rapid eGFR loss and ESRD.

═════════════════════════════════════════════════════════════════════════════════════════════════════════

Important

THE TWO-OUT-OF-THREE CONFIRMATION RULE Urinary albumin excretion fluctuates markedly in response to physiological stressors. Transient, false-positive elevations in UACR occur with strenuous exercise within 24 hours, acute febrile illness, urinary tract infection, marked systemic hypertension, acute decompensated heart failure, severe acute hyperglycemia, and gross hematuria . Therefore, a diagnosis of persistent albuminuria requires documenting abnormal UACR on at least 2 of 3 specimens collected over a 3 to 6-month period .

Evidence-Based Cardiorenal Pharmacotherapeutic Interventions

Renin-Angiotensin System (RAS) Inhibition :

An ACE inhibitor (e.g., lisinopril, enalapril) or Angiotensin Receptor Blocker (ARB) (e.g., losartan, valsartan) is the mandatory first-line agent for patients with diabetes who have hypertension AND persistent albuminuria (UACR >=30 mg/g) .

Mechanism: Selectively dilates the efferent arteriole , reducing intraglomerular hydrostatic pressure and decreasing albumin filtration independent of systemic blood pressure reduction.

Titration & Monitoring: Titrate to the maximum approved, tolerated dose. Serum creatinine and potassium must be evaluated within 1 to 2 weeks after initiating or titrating therapy.

The 30% Creatinine Rule : An increase in serum creatinine of up to 30% from baseline reflects hemodynamic intraglomerular pressure reduction; it is expected, renoprotective, and does NOT warrant drug cessation unless progressive azotemia or uncontrollable hyperkalemia occurs.

Critical Board Trap : ACE inhibitors and ARBs are NOT recommended for primary prevention of diabetic kidney disease in diabetic patients who have normal blood pressure and normal albumin excretion (UACR <30 mg/g). Furthermore, never combine an ACE inhibitor with an ARB ; dual RAS blockade increases the risk of acute kidney injury, severe hyperkalemia, and syncope without conferring additional renal protection (ONTARGET trial).

SGLT2 Inhibitors :

Recommended for all patients with type 2 diabetes, CKD, and eGFR >=20 mL/min/1.73m2 with UACR >=200 mg/g (or eGFR 20-60 mL/min/1.73m2). Proven in CREDENCE, DAPA-CKD, and EMPA-KIDNEY to reduce the composite risk of sustained eGFR doubling, ESRD, and renal death by 30% to 40% .

Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone) :

Finerenone selectively blocks overactivated mineralocorticoid receptors, suppressing downstream proinflammatory and profibrotic pathways in the kidney and heart.

Proven in the FIDELIO-DKD and FIGARO-DKD trials to significantly reduce CKD progression and cardiovascular events in patients with type 2 diabetes with eGFR >=25 mL/min/1.73m2, normal serum potassium (<=4.8 mEq/L), and persistent albuminuria (UACR >=30 mg/g) despite maximally tolerated ACEi/ARB therapy.

Microvascular Complication 2: Diabetic Retinopathy Screening & Staging

Diabetic retinopathy is a highly specific neurovascular complication and remains the leading cause of new-onset legal blindness among working-age adults (aged 20 to 74 years).

Screening Schedule Guidelines

Type 2 Diabetes : Comprehensive dilated eye examination by an ophthalmologist or optometrist at the time of initial diabetes diagnosis , because up to 20% of patients already have retinopathy due to years of unrecognized asymptomatic hyperglycemia. If the initial exam is normal and glycemia is well controlled, exams may be performed every 1 to 2 years ; if retinopathy is present, exams must occur at least annually.

Type 1 Diabetes : Initial dilated eye examination within 5 years after diabetes diagnosis (prepubertal disease duration rarely produces vision-threatening retinopathy), followed by annual examinations.

Pregnancy Considerations : Women with pre-existing type 1 or type 2 diabetes who are planning pregnancy or who become pregnant must receive a comprehensive eye exam in the first trimester and be monitored closely throughout pregnancy and for 1 year postpartum due to the risk of rapid retinopathy progression. (This requirement does not apply to gestational diabetes). SPECTRUM OF DIABETIC RETINOPATHY & MANAGEMENT

Classification Pathognomonic Funduscopic Findings Pathophysiology & Management Strategy
═════════════════════════════════════════════════════════════════════════════════════════════════════

Mild NPDR Microaneurysms alone • Capillary outpouchings from pericyte loss.

• Surveillance: Annual dilated exam.

Moderate NPDR Microaneurysms, 'dot-and-blot' hemorrhages, • Vascular leakage & capillary occlusion.

hard exudates, cotton-wool spots • Hard exudates = lipid deposits.

• Cotton-wool spots = retinal nerve infarcts.

Severe NPDR The '4-2-1 Rule': • High risk (> 50%) of progression to

Severe intraretinal hemorrhages in ALL 4 proliferative disease within 1 year.

quadrants, OR • Close surveillance q3-4 months;

Venous beading in >= 2 quadrants, OR consider early anti-VEGF or PRP.

• Prominent IRMA in >= 1 quadrant

Proliferative NEOVASCULARIZATION of the disc (NVD) or • Retinal ischemia triggers massive VEGF.

Retinopathy (PDR) retina (NVE), preretinal/vitreous hemorrhage, • Fragile new vessels bleed easily.

fibrovascular proliferation, traction • Urgent Treatment: Panretinal Photocoagulation

retinal detachment (PRP) laser or Intravitreal Anti-VEGF.

Diabetic Macular Retinal thickening and hard exudate • Occurs at ANY stage of NPDR or PDR!

Edema (DME) accumulation involving or threatening • LEADING CAUSE OF LEGAL BLINDNESS.

the fovea centralis • First-Line: Intravitreal Anti-VEGF injections

(Aflibercept, Ranibizumab, Faricimab).

═════════════════════════════════════════════════════════════════════════════════════════════════════
Advanced Complications of Proliferative Disease

Vitreous Hemorrhage : Fragile neovascular vessels rupture into the vitreous humor. Patients present with sudden, painless onset of floaters, dark cobwebs, or complete visual blackouts.

Traction Retinal Detachment : Fibrovascular membranes contract, mechanically pulling the neurosensory retina away from the underlying retinal pigment epithelium. Presents with visual field defects ('curtain descending') without flashes/floaters; requires surgical pars plana vitrectomy .

Neovascular Glaucoma : Neovascularization invades the anterior chamber iris and iridocorneal filtration angle, occluding trabecular meshwork outflow, causing intractable intraocular pressure elevation and acute ocular pain.

Microvascular Complication 3: Diabetic Neuropathy & Comprehensive Foot Exam

Diabetic peripheral neuropathy encompasses a diverse spectrum of sensory, motor, and autonomic nerve fiber injury driven by sorbitol accumulation, oxidative stress, and microvascular endoneurial ischemia.

Clinical Phenotypes of Diabetic Neuropathy

Distal Symmetric Polyneuropathy (DSPN) : The classic 'stocking-glove' sensory neuropathy (>80% of neuropathies). Small unmyelinated C-fibers and thinly myelinated A-delta fibers are damaged first (burning pain, electrical shocks, allodynia, thermal sensory loss), followed by large myelinated A-beta fibers (loss of vibration, light touch, proprioception, diminished Achilles reflexes, sensory ataxia).

Diabetic Autonomic Neuropathy (DAN) :

Cardiovascular : Resting tachycardia (>100 bpm), fixed non-variable heart rate, orthostatic hypotension (fall in systolic BP >=20 mmHg or diastolic BP >=10 mmHg within 3 minutes of standing without compensatory heart rate acceleration), and 'silent' painless myocardial infarction.

Gastrointestinal : Diabetic gastroparesis (early satiety, postprandial fullness, nausea, vomiting of undigested food hours after ingestion; confirmed by 4-hour gastric emptying scintigraphy showing >10% retention; treat with small frequent meals, metoclopramide short-term, or erythromycin) and nocturnal diabetic diarrhea.

Genitourinary : Neurogenic bladder (detrusor hyporeflexia, urinary retention, overflow incontinence), erectile dysfunction, retrograde ejaculation.

Sudomotor : Distal anhidrosis (dry, cracked, fissured feet predisposing to skin breakdown) and gustatory facial sweating.

Hypoglycemic Unawareness : Blunting of sympathoadrenal warning signs (palpitations, tremor, anxiety), allowing patients to plunge directly into neuroglycopenic coma.

The Annual Comprehensive Diabetic Foot Examination Protocol

Every adult with diabetes must undergo a comprehensive foot evaluation at least annually to detect risk factors for ulceration and lower-extremity amputation: COMPREHENSIVE DIABETIC FOOT EXAMINATION PROTOCOL

Exam Component Clinical Maneuver & Technique Abnormal Finding & Significance
═════════════════════════════════════════════════════════════════════════════════════════════════════

Visual Inspection Inspect dorsal, plantar, and interdigital skin; • Calluses: pre-ulcerative hyperkeratosis.

assess structural architecture. • Maceration, tinea pedis, onychomycosis.

• Deformities: bunions, hammer/claw toes.

10-g Semmes-Weinstein Apply monofilament perpendicular to skin • Inability to perceive monofilament at
Monofilament Testing until it buckles; hold for 1 to 2 seconds. >= 1 of 10 sites confirms LOSS OF

(The Gold Standard!) Test 10 plantar sites: plantar hallux, 1st, PROTECTIVE SENSATION (LOPS).

3rd, 5th metatarsal heads, midfoot, heel. • Single greatest risk for foot ulceration!

Vibration Perception Apply vibrating 128-Hz tuning fork to the bony • Premature loss of vibration perception

prominence of the dorsal distal hallux. precedes monofilament loss (large fibers).

Pinprick & Reflexes Disposable pin to dorsal hallux; Achilles tap. • Tests small pain fibers & S1 reflex arc.

Vascular Assessment Palpate dorsalis pedis & posterior tibial • Absent pulses or claudication prompts

arteries; evaluate capillary refill & hair loss. Ankle-Brachial Index (ABI) testing.

═════════════════════════════════════════════════════════════════════════════════════════════════════

Ankle-Brachial Index (ABI) Interpretation in Diabetes :

Normal: 0.90 to 1.30.

Peripheral Artery Disease (PAD): ABI < 0.90.

Mönckeberg Medial Calcinosis Trap : An ABI >1.30 or >1.40 indicates non-compressible, heavily calcified medial arterial walls common in diabetes; it does NOT mean normal circulation! In this setting, clinicians must measure the Toe-Brachial Index (TBI) , as digital arteries rarely calcify (normal TBI >=0.70; <0.70 confirms PAD).

Diabetic Peripheral Neuropathic Pain Pharmacotherapy

First-Line FDA-Approved Agents :

Duloxetine : Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) dosed at 60 mg orally once daily. Particularly beneficial if comorbid depression or anxiety.

Pregabalin : Alpha-2-delta calcium channel subunit ligand dosed at 75 to 150 mg twice daily (titrated to 300 mg/day). Adverse effects: sedation, dizziness, peripheral edema.

Alternative Agents :

Gabapentin : Dosed from 300 mg up to 1800-3600 mg/day divided three times daily (requires renal adjustment for eGFR).

Tricyclic Antidepressants (TCAs: Amitriptyline, Nortriptyline) : 25 to 75 mg at bedtime. Highly effective but carry significant anticholinergic side effects, orthostatic hypotension, and QT prolongation; caution in elderly patients.

Topical Capsaicin 8% Patch or topical lidocaine 5% patches.

Opioid Analgesics : Tramadol and opioid narcotics are strongly discouraged by the ADA and AAN due to substantial risks of dependence, tolerance, addiction, and lack of long-term durability.

Acute Charcot Neuroarthropathy (Neuropathic Osteoarthropathy)

Charcot neuroarthropathy is a devastating, limb-threatening complication characterized by progressive joint subluxation, periarticular fractures, and architectural collapse of the foot.

Pathophysiology : Loss of protective sensation + autonomic-mediated arteriovenous shunting (producing bone hyperemia and demineralization) + repetitive unperceived mechanical trauma -> uncontrolled localized inflammatory response with dramatic upregulation of RANK-ligand (RANKL) and proinflammatory cytokines -> unchecked osteoclastic bone resorption, ligamentous laxity, microfractures, joint dislocation, and midfoot collapse.

Clinical Presentation : Acute, unilateral, red, hot, swollen foot and ankle in a patient with profound sensory neuropathy. Pain is often surprisingly mild or absent due to nerve damage.

The Critical Differential : Acute Charcot is frequently misdiagnosed as cellulitis, acute gout, or osteomyelitis :

Cellulitis vs. Charcot Differentiation Maneuver : In Charcot, the skin is completely intact without open ulcers or puncture wounds. Elevating the affected leg above the heart for 5 to 10 minutes causes rapid dissipation of erythema and edema due to venous draining of hyperemic blood. In bacterial cellulitis, erythema and induration persist despite elevation.

Infrared Dermal Thermometry : Skin temperature of the affected foot is >2.0°C (3.6°F) warmer than the contralateral unaffected foot.

Chronic Deformity : Midfoot arch collapse produces the classic 'rocker-bottom foot' deformity with severe plantar bony prominences, leading to chronic intractable plantar ulcers, osteomyelitis, and secondary amputation.

Immediate Management : Strict non-weight-bearing immobilization with Total Contact Casting (TCC) or a customized rigid pneumatic walker until active inflammation has resolved (monitored by infrared skin temperature normalization over 3 to 6 months).

Macrovascular Risk Reduction & Adult Diabetes Immunizations

Cardiovascular disease (coronary artery disease, ischemic stroke, peripheral arterial disease) accounts for >70% of all mortalities in type 2 diabetes. Glycemic control alone exerts only a modest impact on macrovascular outcomes; aggressive multi-factorial risk reduction is mandatory. CARDIOVASCULAR RISK REDUCTION TARGETS & PROTOCOLS

Clinical Domain Guideline-Directed Recommendation Target Goal / Agent Selection
═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Blood Pressure Target < 130/80 mmHg for all diabetic adults • If UACR >= 30 mg/g: ACEi or ARB first-line
with hypertension. Screen at every visit. • If UACR < 30 mg/g: ACEi, ARB, CCB, or thiazide

Statin Therapy: Ages 40 to 75 years without established ASCVD: • Target: >= 30-49% LDL-C reduction
Primary Prevention MODERATE-INTENSITY STATIN • Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg
If multiple ASCVD risk factors or 10-yr risk • If high risk: HIGH-INTENSITY STATIN
>= 20%: HIGH-INTENSITY STATIN (Atorvastatin 40-80 mg, Rosuva 20-40 mg)
Target LDL-C < 70 mg/dL

Statin Therapy: All ages with ESTABLISHED ASCVD: • HIGH-INTENSITY STATIN
Secondary Prevention HIGH-INTENSITY STATIN • Target LDL-C < 55 mg/dL
If LDL-C >= 55 mg/dL: Add Ezetimibe 10 mg;
if still >= 55 mg/dL: Add PCSK9 inhibitor

Antiplatelet Therapy: All diabetic patients with established ASCVD: • ASPIRIN 81 mg daily indefinitely

Secondary Prevention Secondary prevention against recurrent events • Clopidogrel 75 mg daily if aspirin-allergic

Antiplatelet Therapy: Selected high-risk individuals after shared • Routine aspirin for primary prevention is

Primary Prevention decision-making; not routinely recommended NO LONGER recommended due to major bleeding!

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Comprehensive Adult Immunization Schedule for Diabetes

Because diabetes induces impaired neutrophil chemotaxis, blunted phagocytosis, and defective cell-mediated immunity, patients are vulnerable to severe vaccine-preventable infections: MANDATED ADULT DIABETIC IMMUNIZATION SCHEDULE

Vaccine Target Recommended Schedule & Formulations
═════════════════════════════════════════════════════════════════════════════════════════════════════

Influenza Annual quadrivalent inactivated (IIV4) or recombinant (RIV4) vaccine.

Pneumococcal Disease Ages 19 through 64 years with diabetes:

• Single dose of PCV20 (Prevnar 20) alone, OR

PCV15 (Vaxneuvance) followed by PPSV23 (Pneumovax 23) >= 1 year later.
If PPSV23 received previously: give PCV20 or PCV15 >= 1 year after PPSV23.

Hepatitis B 2-dose (Heplisav-B at 0, 1 mo) or 3-dose (Engerix-B at 0, 1, 6 mo) series
for ALL unvaccinated adults with diabetes aged 19 through 59 years

(due to transmission risk via fingerstick glucometers); aged >=60 per discretion.

Respiratory Syncytial Virus Single dose of RSV vaccine (Arexvy or Abrysvo) for adults aged >=60 years

(RSV) with chronic metabolic disorders including diabetes mellitus.

COVID-19 Annual updated seasonal COVID-19 vaccine formulation.

Tetanus, Diphtheria, One dose of Tdap if not received previously, followed by Td or Tdap booster

Pertussis (Tdap/Td) every 10 years.

Herpes Zoster 2-dose series of Recombinant Zoster Vaccine (Shingrix) at months 0 and 2-6

for all adults aged >=50 years (and immunocompromised adults >=19 years).